Around 220,000 people with 'greatest need' are expected to receive Mounjaro through the NHS over the next three years ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema ...

A recent study reveals a concerning trend. Many Indian households have all adults overweight or obese. ICMR-NICPR researchers ...

Many people believe that being overweight always leads to type 2 diabetes, but the truth is more complicated. While being ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...

Wells Fargo has expressed its expectation that Sweetgreen, Inc.’s (NYSE:SG) fundamentals will improve in the second half of ...

STATEN ISLAND, N.Y. — Starting Sunday, truck drivers heading toward Staten Island via the Brooklyn-Queens Expressway will ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...